MPR

FDA Accepts NDA for K-911 to Reduce Intraocular Pressure in Glaucoma

The novel nitric oxide-donating prostaglandin analog met noninferiority endpoints vs latanoprost across two phase 3 trials.
MPR

Tezepelumab Meets Coprimary Endpoints in Phase 3 EoE Trial

Phase 3 CROSSING trial data show tezepelumab significantly improved histologic remission and dysphagia in patients aged 12 and older with eosinophilic esophagitis.
MPR

Cortical Atrophy in Early-Onset Alzheimer Disease Can Predict Progression to Dementia

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...
MPR

Paternal Valproate Exposure Not Linked to Offspring Neurodevelopmental Disorders

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...